65,437 trials
Leiomyoma · Uterine Hemorrhage
Primary: Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment in Treatment Course 1 — 0.0; 42.0; 54.8 percentage of participants
COPD
Primary: Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4 — 0.203; 0.209; 0.257; 0.196 Liters — p=<0.001
Healthy Volunteers
Primary: Number of Participants With Colds With at Least Moderate Intensity — 4; 2; 7; 0 Participants
Hepatitis C Infection · HIV
Primary: Number of Participants With Sustained Virological Response 6 Months After Treatment Discontinuation — 10 Participants
Heart Failure · Depressive Symptoms
Primary: Depressive Symptoms — 8.6; 9.8 units on a scale — p=0.21
Quality of Life · Breast Cancer
Primary: PROMIS Physical Functioning — 44.61; 53.82; 45.07; 52.99 units on a scale
Migraine Headache
Primary: Verbal Pain Score at 60 Minutes — 4.5; 4.9 units on a scale (0-10)
HIV
Primary: Number of Participants Willing to Undergo Rapid HIV Testing — 318; 60 Participants
Health Knowledge, Attitudes, Practice
Primary: Understanding of the Summary Content — 7.0; 7.0 units on a scale
Migraine
Primary: Number of Participants With a MLA Within 24 Hours of Challenge Agent Infusion — 1; 1; 8; 6 Participants
Peripheral Artery Disease
Primary: Change in Vasodilator Capacity — 16.2; 16.4; 16.5; 14.2 ml/100ml tissue/min
Erosive Esophagitis
Primary: Percentage of Participants With Endoscopic Healing of Erosive Esophagitis During the 8-Week Treatment Phase — 92.4; 91.3 percentage of participants
Small Fiber Neuropathy
Primary: AFI-intensity After Nociceptive Stimulation — 0.60; 0.25; 0.50 unitless
Hepatitis C Viral · Chronic Kidney Disease stage3
Primary: Change of Serum Endostatin Level (ng/mL) From Baseline to 3 Months — 156; 176 ng/mL
Metabolic Syndrome · Dyslipidemia · Obesity, Abdominal
Primary: Total Cholesterol Levels — 5.8; 5.9 mmol/L